

RECEIVED
MAR 26 2002
TECH CENTER 1600/2900

Applicants:	Williams, et al.
Serial No.:	09/529,053
Filed:	April 6, 2000
For:	Anti-Viral Uses of Leflunomide Products
Docket No:	29666/35415
Art Unit:	1617
Examiner:	S. Wang

March 14, 2002

Michael F. Borun
Registration No. 25,447
Attorney for Applicant(s)

March 14, 2002



IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

PATENT

TECH CENTER 1600/2900

MAR 26 2002

RECEIVED

Applicants: Williams, et al.

Serial No.: 09/529,053

Filed: April 6, 2000

For: Anti-Viral Uses of
Leflunomide Products


Docket No: 29666/35415

Art Unit: 1617

Examiner: S. Wang

I hereby certify that this paper is
being deposited with the United
States Postal Service with sufficient
postage as first class mail in an
envelope addressed to:
Commissioner for Patents,
Washington, D.C. 20231 on this
date:

March 13, 2002


Michael F. Borun
Registration No. 25,447
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

Submitted herewith is a copy (with English translation as appropriate) of an Official Search Report of the PCT Patent Office in counterpart foreign application No. US99/05326 filed March 11, 1999.

03/22/2002 SHINASS1 00000087 09529053

01 FC:126

180.00 OP

TIME OF FILING

This information disclosure statement is being filed:

- ☐ 1. with the application or within three months of the filing date of the application or date of entry into the national stage of an international application or, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last. In accordance with 37 CFR §1.97(b), no certification or fee is required.
- ☒ 2. after the time period specified in paragraph 1 above, but, to the best of the undersigned's knowledge, before the mailing date of a final action under 37 CFR §1.113 or notice of allowance under 37 CFR §1.311. Therefore, in accordance with 37 CFR §1.97(c), submitted herewith is:
 - A. ☒ a certification as specified in 37 CFR §1.97(e).
 - B. ☒ the fee set forth in 37 CFR §1.17(p) for submission of an information disclosure statement under 37 CFR §1.97(c).
- 3. after the mailing date of either a final action under 37 CFR §1.113 or a notice of allowance under 37 CFR §1.311, whichever occurs first, but before payment of the issue fee. Therefore, Applicant submits herewith:
 - A. a certification as specified in 37 CFR §1.97(e);
 - B. the petition fee set forth in 37 CFR §1.17(i); and
 - C. the accompanying petition under 37 CFR §1.97(d).

CERTIFICATION

(only used if No. 2 or No. 3 above is checked)

The person(s) signing below certify

(check appropriate paragraph)

- ☒ that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 CFR §1.97(e)(1).

OR

- ☐ that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement. 37 CFR §1.97(e)(2).

METHOD OF PAYMENT


- ☐ No fee is required.
- ☒ Attached is a check in the amount of \$ 180.00.

The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855. A copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By:


Michael F. Borun
Reg. No: 25,447

March 13, 2002